{"id":919499,"date":"2025-12-15T07:41:42","date_gmt":"2025-12-15T12:41:42","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/neogenomics-announces-that-natera-has-voluntarily-withdrawn-its-appeal-in-ongoing-radar-patent-litigation\/"},"modified":"2025-12-15T07:41:42","modified_gmt":"2025-12-15T12:41:42","slug":"neogenomics-announces-that-natera-has-voluntarily-withdrawn-its-appeal-in-ongoing-radar-patent-litigation","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neogenomics-announces-that-natera-has-voluntarily-withdrawn-its-appeal-in-ongoing-radar-patent-litigation\/","title":{"rendered":"NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation<\/b><\/p>\n<p class=\"bwalignc\"><i>NeoGenomics moving toward a full U.S. clinical launch of its RaDaR ST molecular residual disease (MRD) assay in Q1 2026<\/i><\/p>\n<p>FORT MYERS, Fla.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.neogenomics.com%2F&amp;esheet=54376553&amp;newsitemid=20251215508360&amp;lan=en-US&amp;anchor=NeoGenomics%2C+Inc.&amp;index=1&amp;md5=69f410c726b45816fea8467f82722e3f\">NeoGenomics, Inc.<\/a> (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that Natera voluntarily dismissed its appeal (and NeoGenomics thus dismissed its cross-appeal) of the North Carolina District Court\u2019s August 2025 ruling. The dismissal will leave in place the ruling in NeoGenomics\u2019 favor.\n<\/p>\n<p>\nThat ruling, issued by the District Court for the Middle District of North Carolina, granted NeoGenomics\u2019 motion for summary judgment and held that Natera\u2019s asserted patent claims are invalid for claiming ineligible subject matter. The Court dismissed Natera\u2019s claims against NeoGenomics with prejudice and entered a declaratory judgment of invalidity with respect to both of Natera\u2019s asserted patents.\n<\/p>\n<p>\n\u201cWe are very pleased that Natera has voluntarily decided to end this litigation process,\u201d said Tony Zook, CEO of NeoGenomics. \u201cWhile we were confident in our position, this latest development nonetheless allows us to focus our full attention on executing a robust clinical launch of RaDaR ST in the first quarter of next year.\u201d\n<\/p>\n<p><b>About NeoGenomics<\/b><\/p>\n<p>\nNeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom.\n<\/p>\n<p><b>Forward Looking Statements<\/b><\/p>\n<p>\nThis press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as \u201canticipate,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201ccan,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cforecast,\u201d \u201cgoal,\u201d \u201cproject,\u201d \u201cguidance,\u201d \u201cpotential\u201d and other words of similar meaning, although not all forward-looking statements include these words. These forward-looking statements include statements regarding the Company\u2019s plans to launch its RaDaR ST molecular residual disease assay in the first quarter of 2026. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Applicable risks and uncertainties include, among others, the risks identified under the heading &#8220;Risk Factors&#8221; contained in the Company&#8217;s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company&#8217;s other filings with the Securities and Exchange Commission.\n<\/p>\n<p>\nWe caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=54376553&amp;newsitemid=20251215508360&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=2&amp;md5=20307cf05290b832f9edfbd60adf7d55\">www.sec.gov<\/a> and in the \u201cInvestors\u201d section of our website at ir.neogenomics.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251215508360r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20251215508360\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20251215508360\/en\/<\/a><\/span><\/p>\n<p><b>Investor Contact<br \/>\n<\/b><br \/>Kendra Webster<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:InvestorRelations@neogenomics.com\">InvestorRelations@neogenomics.com<\/a><\/p>\n<p><b>Media Contact<br \/>\n<\/b><br \/>Andrea Sampson<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:asampson@sampsonprgroup.com\">asampson@sampsonprgroup.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Florida United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Health Radiology Pharmaceutical Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251215508360\/en\/2670109\/3\/NeoGenomics.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation NeoGenomics moving toward a full U.S. clinical launch of its RaDaR ST molecular residual disease (MRD) assay in Q1 2026 FORT MYERS, Fla.&#8211;(BUSINESS WIRE)&#8211;NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that Natera voluntarily dismissed its appeal (and NeoGenomics thus dismissed its cross-appeal) of the North Carolina District Court\u2019s August 2025 ruling. The dismissal will leave in place the ruling in NeoGenomics\u2019 favor. That ruling, issued by the District Court for the Middle District of North Carolina, granted NeoGenomics\u2019 motion for summary judgment and held that Natera\u2019s asserted patent claims are invalid for claiming ineligible subject matter. The &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neogenomics-announces-that-natera-has-voluntarily-withdrawn-its-appeal-in-ongoing-radar-patent-litigation\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-919499","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neogenomics-announces-that-natera-has-voluntarily-withdrawn-its-appeal-in-ongoing-radar-patent-litigation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation NeoGenomics moving toward a full U.S. clinical launch of its RaDaR ST molecular residual disease (MRD) assay in Q1 2026 FORT MYERS, Fla.&#8211;(BUSINESS WIRE)&#8211;NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that Natera voluntarily dismissed its appeal (and NeoGenomics thus dismissed its cross-appeal) of the North Carolina District Court\u2019s August 2025 ruling. The dismissal will leave in place the ruling in NeoGenomics\u2019 favor. That ruling, issued by the District Court for the Middle District of North Carolina, granted NeoGenomics\u2019 motion for summary judgment and held that Natera\u2019s asserted patent claims are invalid for claiming ineligible subject matter. The &hellip; Continue reading &quot;NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/neogenomics-announces-that-natera-has-voluntarily-withdrawn-its-appeal-in-ongoing-radar-patent-litigation\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-15T12:41:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251215508360r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neogenomics-announces-that-natera-has-voluntarily-withdrawn-its-appeal-in-ongoing-radar-patent-litigation\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neogenomics-announces-that-natera-has-voluntarily-withdrawn-its-appeal-in-ongoing-radar-patent-litigation\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation\",\"datePublished\":\"2025-12-15T12:41:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neogenomics-announces-that-natera-has-voluntarily-withdrawn-its-appeal-in-ongoing-radar-patent-litigation\\\/\"},\"wordCount\":613,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neogenomics-announces-that-natera-has-voluntarily-withdrawn-its-appeal-in-ongoing-radar-patent-litigation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251215508360r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neogenomics-announces-that-natera-has-voluntarily-withdrawn-its-appeal-in-ongoing-radar-patent-litigation\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neogenomics-announces-that-natera-has-voluntarily-withdrawn-its-appeal-in-ongoing-radar-patent-litigation\\\/\",\"name\":\"NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neogenomics-announces-that-natera-has-voluntarily-withdrawn-its-appeal-in-ongoing-radar-patent-litigation\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neogenomics-announces-that-natera-has-voluntarily-withdrawn-its-appeal-in-ongoing-radar-patent-litigation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251215508360r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-12-15T12:41:42+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neogenomics-announces-that-natera-has-voluntarily-withdrawn-its-appeal-in-ongoing-radar-patent-litigation\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neogenomics-announces-that-natera-has-voluntarily-withdrawn-its-appeal-in-ongoing-radar-patent-litigation\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neogenomics-announces-that-natera-has-voluntarily-withdrawn-its-appeal-in-ongoing-radar-patent-litigation\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251215508360r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251215508360r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neogenomics-announces-that-natera-has-voluntarily-withdrawn-its-appeal-in-ongoing-radar-patent-litigation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/neogenomics-announces-that-natera-has-voluntarily-withdrawn-its-appeal-in-ongoing-radar-patent-litigation\/","og_locale":"en_US","og_type":"article","og_title":"NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation - Market Newsdesk","og_description":"NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation NeoGenomics moving toward a full U.S. clinical launch of its RaDaR ST molecular residual disease (MRD) assay in Q1 2026 FORT MYERS, Fla.&#8211;(BUSINESS WIRE)&#8211;NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that Natera voluntarily dismissed its appeal (and NeoGenomics thus dismissed its cross-appeal) of the North Carolina District Court\u2019s August 2025 ruling. The dismissal will leave in place the ruling in NeoGenomics\u2019 favor. That ruling, issued by the District Court for the Middle District of North Carolina, granted NeoGenomics\u2019 motion for summary judgment and held that Natera\u2019s asserted patent claims are invalid for claiming ineligible subject matter. The &hellip; Continue reading \"NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/neogenomics-announces-that-natera-has-voluntarily-withdrawn-its-appeal-in-ongoing-radar-patent-litigation\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-15T12:41:42+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251215508360r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neogenomics-announces-that-natera-has-voluntarily-withdrawn-its-appeal-in-ongoing-radar-patent-litigation\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neogenomics-announces-that-natera-has-voluntarily-withdrawn-its-appeal-in-ongoing-radar-patent-litigation\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation","datePublished":"2025-12-15T12:41:42+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neogenomics-announces-that-natera-has-voluntarily-withdrawn-its-appeal-in-ongoing-radar-patent-litigation\/"},"wordCount":613,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neogenomics-announces-that-natera-has-voluntarily-withdrawn-its-appeal-in-ongoing-radar-patent-litigation\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251215508360r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neogenomics-announces-that-natera-has-voluntarily-withdrawn-its-appeal-in-ongoing-radar-patent-litigation\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/neogenomics-announces-that-natera-has-voluntarily-withdrawn-its-appeal-in-ongoing-radar-patent-litigation\/","name":"NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neogenomics-announces-that-natera-has-voluntarily-withdrawn-its-appeal-in-ongoing-radar-patent-litigation\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neogenomics-announces-that-natera-has-voluntarily-withdrawn-its-appeal-in-ongoing-radar-patent-litigation\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251215508360r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-12-15T12:41:42+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neogenomics-announces-that-natera-has-voluntarily-withdrawn-its-appeal-in-ongoing-radar-patent-litigation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/neogenomics-announces-that-natera-has-voluntarily-withdrawn-its-appeal-in-ongoing-radar-patent-litigation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neogenomics-announces-that-natera-has-voluntarily-withdrawn-its-appeal-in-ongoing-radar-patent-litigation\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251215508360r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251215508360r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neogenomics-announces-that-natera-has-voluntarily-withdrawn-its-appeal-in-ongoing-radar-patent-litigation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/919499","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=919499"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/919499\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=919499"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=919499"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=919499"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}